Ignite Creation Date:
2024-10-26 @ 3:43 PM
Last Modification Date:
2024-10-26 @ 3:43 PM
Study NCT ID:
NCT06656494
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-10-21
Brief Title:
ICP-248 in Combination with Azacitidine in Treatment-Naïve Subjects with Acute Myelogenous LeukemiaAML or Previously Treated RelapsedRefractory Subjects with Acute Myelogenous LeukemiaRR AML
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Phase 1 Study of ICP-248 in Combination with Azacitidine in Treatment-Naïve Subjects with Acute Myelogenous Leukemia Who Are Not Eligible for Standard Anthracycline-Based Induction or Previously Treated RelapsedRefractory Subjects with Acute Myelogenous Leukemia
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Evaluate the safety tolerability pharmacokinetics and preliminary efficacy of ICP-248 in Combination with azacitidine in Patients with Acute Myelogenous Leukemia This study consists of two parts Part 1 dose escalation period and Part 2 dose expansion period
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None